Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC

CisionPR Newswire_2.png

VANCOUVER, British Columbia and SAN DIEGO, June 4, 2019 - In March 2018, PhoenixMD and STA Pharmaceutical (WuXi STA) entered into a major manufacturing agreement, and have since produced a multi kilogram drug supply for PMD-026 under GMP manufacturing practices. This represents a significant milestone, accelerating PhoenixMD's Phase I readiness.

Read the story  here

REDUCING R(I)SK IN TNBC

BioCentury.jpeg

VANCOUVER, British Columbia and SAN DIEGO, Feb. 07 2019 - Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in 80% of TNBC tumors, Phoenix aims to develop a targeted therapeutic, and has partnered with Roche on a companion diagnostic.

Read the story on BioCentury here

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

CisionPR Newswire_2.png

VANCOUVER, British Columbia and SAN DIEGO, Jan. 16 2019 - We're excited to announce our collaboration with Roche to develop a companion diagnostic (CDx) in TNBC. The Roche/PhoenixMD CDx will measure activated RSK2 in human tumors and will identify patients that will ultimately benefit from our drug PMD-026.

Read the full story on PR Newswire here

Navigating an Ocean of Drug Development & Manufacturing Outsourcing with PhoenixMD

img-event-outsourced-pharma.png

August 22-23 2018 - Outsourced Pharma- San Diego California

Case Study: Inside A (Small) Drug Sponsor - (Big) CDMO Relationship

Dr. Sandra Dunn, founder and CEO of Phoenix Molecular Designs, and members of her senior leadership team, presented a detailed case study and insight into her virtual biotech’s working relationship with CDMO WuXi (San Diego operations), and toxicology service provider Paracelsus, Inc.

“As breast cancer is the #1 cause of death in women world-wide it is a global problem that requires a global solution.  This is why our strategy is to outsource several aspects of our drug development so that we have the opportunity to work with the best and brightest, leveraging years of deep industry experience to catalyze our path to commercialization.Each day women are dying of this terrible disease and working with a highly efficient outsourced team shortens our development time so that we are able to get new medicine to patients sooner” - Dr. Sandra Dunn, CEO and ~30 year veteran breast cancer researcher.

 
From Left to right: Erik flahive, Grace furman, Gerrit los, wenjie Li, youchu wang and sandra dunn

From Left to right: Erik flahive, Grace furman, Gerrit los, wenjie Li, youchu wang and sandra dunn

 

PhoenixMD selected to participate in the Outsourced Pharma Event (August 21-22, 2018) in San Diego, California

Outsourced Pharma.png

May 24, 2018 - In this all San Diego panel of three companies, Dr. Sandra Dunn, founder and CEO of Phoenix Molecular Designs, and members of her senior leadership team will present a detailed case study and insight into her virtual biotechnology company’s working relationship with CDMO WuXi (San Diego operations) and toxicology service provider Paracelsus, Inc. on August 22, 2018.

For the complete agenda for this session “Navigating an Ocean of Drug Development & Manufacturing Outsourcing” click here

PhoenixMD team meet in San Diego for first IND planning meeting

First IND planning meeting_crop.jpg

April 20, 2018 - A very productive first IND planning meeting with the PhoenixMD pre-clinical and clinical operations teams was held last Friday at our JLabs location in San Diego.

Pictured are our clinical operations division Dr. Erik Flahive, Dr. Gerrit Los, Dr. Grace Furman and Dr. Terry Rugg (pictured left to right). Our CEO Dr. Sandra Dunn was on site to discuss our plans forward towards a successful filing with the FDA.

Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND

CisionPR Newswire_2.png

VANCOUVER, British Columbia and SAN DIEGO, April 16, 2018 - Phoenix Molecular Designs have entered into a collaboration with STA Pharmaceutical Co., Ltd (STA), a WuXi AppTec group company, to manufacture the PMD-026 needed for IND-enabling toxicology studies and a Phase I study.

Read the full press release here

Phoenix Molecular Designs team members meet with investors to discuss partnership opportunities at premier Life Science events in the US.

RESI logo.png
biocom_logoh.png

January 9, 2018 - Dr. Sandra Dunn joined 500+ companies at the annual Redefining Early Stage Investments (RESI) conference in San Francisco, one of the most important investor events in the Biotech calendar. She was also invited to attend the WuXi Global Forum, to hear from the industry thought leaders about their thoughts on the rapidly changing landscape of the Biotech industry.

 

March 1, 2018 - Our CSO Dr. Gerrit Los attended the 2018 premier partnering event of the year, the 8th annual BIOCOM Global Life Science Partnering Conference in La Jolla, California. This conference was an exclusive forum to showcase our work to wide range of investors.

Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer

CisionPR Newswire_2.png

July 17, 2017 - Leading expert in Oncology, Pharmacology and Translational Medicine, Dr. Gerrit Los has been appointed as our new Chief Scientific Officer. With his expertise and guidance, PhoenixMD is advancing our program to bring our RSK kinase inhibitors to the clinic to treat the most devastating of breast cancers, Triple Negative Breast Cancer. Read the full press release here

San Diego trade mission to Vancouver announces Phoenix Molecular Designs' expansion into the USA

June 23, 2017 - The mayor of San Diego, Kevin Faulconer and a trade mission of 26 delegates is visiting the Phoenix Molecular Designs head office to announce our expansion into the US. By expanding our operations into San Diego, PhoenixMD will have access to more talent in drug development, helping to accelerate the development of our TNBC treatment. Read the full press release here

 
L-R: Mayor Kevin Faulconer, Frank Stonebanks (Venture Partner, Lumira Capital), Dr. SandRa Dunn (CEO, Phoenix) and Dr. Lesley Esford (President, LifeSciences BC)

L-R: Mayor Kevin Faulconer, Frank Stonebanks (Venture Partner, Lumira Capital), Dr. SandRa Dunn (CEO, Phoenix) and Dr. Lesley Esford (President, LifeSciences BC)

 

Phoenix Molecular Designs Announces New Preclinical Data for Targeted Triple Negative Breast Cancer (TNBC) Therapy

 May 25, 2017 - VANCOUVER, British Columbia and SAN DIEGO.  Phoenix Molecular Design's latest preclinical study results show that their lead compound PMD-026 demonstrates 70% inhibition of ribosomal S6 kinase (RSK) signaling, blocking TNBC tumor growth and with no adverse effects in mice. 

Read the full press release here

"War on Cancer" - PhoenixMD featured in Life Sciences 2017

lifesciencesbclogo3-270x192.jpg

April 26 2017 - Hot off the press is Life Sciences BC's annual publication featuring an article on the personal story behind Phoenix Molecular Designs from our founder and CEO, Dr. Sandra Dunn. Read about our work (page 16) and a range of other inspiring women leaders in British Columbia's burgeoning Biotech industry here

 
CEO and founder of Phoenixmd, Dr. Sandra Dunn

CEO and founder of Phoenixmd, Dr. Sandra Dunn

 

PhoenixMD attends the Biocom Global Life Science Partnering Conference in La Jolla, CA

March 06, 2017 - PhoenixMD is proud to be one of ten companies chosen to attend this outstanding one-of-a-kind event last week. This was an amazing opportunity for our CEO Dr. Sandra Dunn to showcase our accomplishments and to explore possibilities for partnership with some of the biggest players in the industry.

Thank you to the the Canadian Trade Commissioner Service and Consulate General of Canada in LA for their support and for promoting Phoenix at this event. Many thanks also to Dr. Dan Zekzer for being a wonderful coach.

 
The Canadian Team at the Biocom Global Life Science Partnerning Conference in La Jolla, CA, March 1-2, 2017. PhoenixMD CEO Dr. Sandra Dunn 4th from left, Dr. Dan Zekzer on the right.

The Canadian Team at the Biocom Global Life Science Partnerning Conference in La Jolla, CA, March 1-2, 2017. PhoenixMD CEO Dr. Sandra Dunn 4th from left, Dr. Dan Zekzer on the right.